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Erythropoietin (EPO) is a hormone that induces red blood cell production. In its recombinant form, EPO is 
the one of most prescribed drugs to treat anemia, including that arising in cancer patients. In randomized 
trials, EPO administration to cancer patients has been associated with decreased survival. Here, we investi-
gated the impact of EPO modulation on tumorigenesis. Using genetically engineered mouse models of breast 
cancer, we found that EPO promoted tumorigenesis by activating JAK/STAT signaling in breast tumor-initi-
ating cells (TICs) and promoted TIC self renewal. We determined that EPO was induced by hypoxia in breast 
cancer cell lines, but not in human mammary epithelial cells. Additionally, we demonstrated that high levels 
of endogenous EPO gene expression correlated with shortened relapse-free survival and that pharmacologic 
JAK2 inhibition was synergistic with chemotherapy for tumor growth inhibition in vivo. These data define an 
active role for endogenous EPO in breast cancer progression and breast TIC self-renewal and reveal a potential 
application of EPO pathway inhibition in breast cancer therapy.
Introduction
The glycoprotein hormone erythropoietin (EPO) is principally 
produced in the tubulointerstitial cells of the kidney in adults 
and is the chief regulator of erythropoiesis. EPO couples red 
blood cell production to tissue oxygenation through an oxygen-
sensing system mediated by the HIF family of transcription fac-
tors, of which there are 3 family members (HIF1α, HIF2α, and 
HIF3α) (1). Genetic evidence suggests that EPO is regulated at the 
transcriptional level by HIF2α (2–5).
EPO activates the transmembrane EPO receptor (EPO-R), 
located primarily on erythroid progenitor cells (6–8). The EPO-R 
lacks intrinsic kinase activity and thus relies on its association 
with the intracellular kinase JAK2 to initiate context-dependent 
signal transduction cascades such as the PI3K, MEK/ERK, 
and STAT pathways (6–9).
Hypoproliferative anemia affects over 75% of all cancer patients 
and recombinant human EPO (rHuEPO) is FDA approved for the 
treatment of chemotherapy-induced anemia (10). Its positive effects 
on quality of life led to its widespread use in clinical oncology. How-
ever, recently, several prospective, randomized trials have shown that 
administration of erythropoiesis-stimulating agents (ESAs) during 
treatment results in both a shorter time to tumor progression and 
overall survival of cancer patients (11–17). Nonetheless, the nega-
tive impact of EPO in cancer patients remains controversial, as some 
other studies have also shown no detrimental effect of EPO if the 
target hemoglobin (Hgb) is approximately 10 g/dl (18–21).
A number of preclinical studies have examined the role of EPO 
with a wide range of in vitro findings (6–8, 22–27). In contrast, 
in various in vivo xenograft tumor models, exogenous EPO does 
not significantly promote tumor growth or result in resistance to 
therapy (6–8, 22, 23) with the exception of Lewis lung carcinoma 
xenografts and carcinogen-induced fibrosarcomas (28). Therefore, 
there is a disconnect between the in vitro results that suggest a pro-
tumorigenic effect of EPO and the in vivo results, which do not.
We found that exogenous EPO did not have appreciable effects 
on cellular proliferation or protect from chemotherapy-induced 
apoptosis in vitro. In contrast, EPO promoted in vivo tumor pro-
gression of 2 autochthonous genetically engineered murine mod-
els (GEMMs) of breast cancer as well as cell lines derived from 
GEMM tumors when injected orthotopically. While the bulk 
populations of these tumor cell lines were not responsive to EPO 
in vitro, treatment of breast tumor-initiating cells (TICs) with 
EPO activated JAK/STAT signaling as well as promoted their self 
renewal. Finally, we show several lines of evidence that endogenous 
EPO plays a protumorigenic role in breast tumorigenesis. We show 
that breast cancer cells as well as tumor-associated endothelial 
cells can produce EPO and that EPO expression within human 
breast tumors correlates negatively with progression-free survival. 
Additionally, JAK2 inhibition cooperates with chemotherapy to 
decrease tumor growth. These findings suggest an active role for 
endogenous EPO in tumor progression and argue for a potential 
role of targeting the EPO pathway in breast cancer therapy.
Results
EPO does not affect human breast cancer cell lines in vitro. Based on pre-
viously reported data suggesting a protumorigenic role of EPO in 
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breast cancer, we wished to explore the impact of EPO in vitro. In 
our hands, neither proliferation nor cell-cycle progression were 
altered by increasing amounts of EPO (Figure 1, A and B). Similarly, 
EPO did not appear to protect against chemotherapy-induced apop-
tosis (Figure 1, C and D). Despite several of these cell lines express-
ing the EPO-R, exogenous EPO did not appear to appreciably 
increase JAK/STAT signaling (Supplemental Figure 1, A and B; sup-
plemental material available online with this article; doi:10.1172/
JCI69804DS1). Thus, based on these assays, in our hands, EPO does 
not appear to be relevant for the in vitro growth properties or sur-
vival of breast cancers cells grown as monolayer cultures.
EPO decreases the survival of breast GEMMs but has no effect on 
GEMM-derived cell lines in vitro. The majority of in vivo studies have 
not demonstrated a protumorigenic effect of EPO (6, 7, 22, 23, 
29–32). We noted that these studies utilized xenografts or carcin-
ogen-induced tumors and hypothesized that GEMMs would serve 
as a more relevant context to address this issue, providing tumors 
arising in a native setting and allowing us to administer EPO for 
longer intervals. To this end, we administered clinically relevant 
doses of exogenous EPO that minimally elevated Hgb and Hct 
levels (Supplemental Figure 2A) to 2 independent breast cancer 
GEMMs (MMTV-Neu and C3-Tag) (33, 34). The percentage of mice 
living over time was significantly shorter in EPO-treated MMTV-
Neu mice (P = 0.05, Figure 2A), with a median survival of 20.6 and 
15.7 weeks in the saline- and EPO-treated groups respectively. 
Similar results were seen in the C3-Tag model (P = 0.04, Figure 2A). 
The decreased percentage of mice living appeared to be a reflection 
of a shortened tumor-free survival (Supplemental Figure 2, B and 
C). There were no apparent differences in H&E histology between 
PBS- and EPO-treated tumors (Figure 2A) or their proliferation 
and vascularity as assessed by Ki67 and CD31 staining (Supple-
mental Figure 3, A and B).
We next generated cell lines from C3-Tag tumors and obtained 
the NT2 line derived from MMTV-Neu tumors (E. Jaffee, Johns 
Hopkins University, Baltimore, Maryland, USA). We confirmed 
the origin of the C3-Tag cells by the detection of SV40 large T anti-
gen (Supplemental Figure 4A). Similar to the human breast can-
cer cell lines, EPO did not affect proliferation (Figure 2, B and C) 
or chemotherapy-induced apoptosis (Figure 2, D and E) of these 
primary murine cell lines despite expressing detectable EPO-R 
Figure 1
EPO does not affect human breast cancer cell lines in vitro. (A) Indicated cell lines were cultured in the presence of increasing concentrations of 
EPO (1, 5, and 10 IU/ml, replenished every other day), and proliferation was detected by MTT assay. (B) Cell lines were cultured in the presence 
of PBS or EPO (1 IU/ml) for 16 hours and EdU for 1 hour. They were then analyzed for EdU incorporation by flow cytometry. (C) Indicated cell 
lines were treated with vehicle, etoposide (50 μM), or etoposide (50 μM) and EPO (10 IU/ml) for 24 hours. Whole-cell extracts were Western blot-
ted with the indicated antibodies. (D) Indicated cell lines were treated with DMSO, etoposide (50 μM), or etoposide (50 μM) and EPO (10 IU/ml) 
for 24 hours, then stained with PI and antibodies against annexin V. The percentages of cells that were annexin V positive and PI negative were 
quantified by flow cytometry. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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(Supplemental Figure 4B). Thus, while EPO is protumorigenic 
in vivo, it did not affect proliferation or apoptosis of C3-Tag and 
MMTV-Neu cell lines in vitro.
EPO increases the growth of orthotopically implanted C3-Tag and 
MMTV-Neu tumors. We next asked whether orthotopic reimplan-
tation of luciferase-expressing C3-Tag cells [C3-Tag-luc] into the 
mammary fat pad would affect the cell’s sensitivity to exogenous 
EPO. To this end, C3-Tag-luc cells were orthotopically implanted 
into syngeneic female FVB/N mice. EPO significantly increased 
tumor burden at 21 days as measured by Xenogen IVIS (P ≤ 0.05; 
Figure 3, A and B) and caliper measurements (Supplemental 
Figure 5A) and was associated with the more rapid growth of 
established tumors (Supplemental Figure 5B) and a significantly 
decreased percentage of mice living over time (P = 0.005, Supple-
mental Figure 5C). Exogenous EPO also promoted the growth of 
NT2 cells orthotopically implanted into FVB mice (Figure 3C).
Finally, exogenous EPO decreased the percentage of mice alive 
that had been tail-vein injected with C3-Tag cells (an experimen-
tal model of metastases) (Figure 3D) as well as C3-Tag tail-vein–
injected mice concurrently treated with carboplatin (Figure 3E). 
Figure 2
EPO decreases the percentage of breast cancer GEMMs living over time yet does not affect breast cancer GEMM cell lines in vitro. (A) Kaplan-
Meier survival curves of MMTV-Neu and C3-Tag mice randomized to saline or EPO (500 IU/kg BIW) injections. (MMTV-Neu: P = 0.05, C3-Tag: 
P = 0.04). Tumors were sectioned and H&E stained. (B) Indicated cell lines were cultured in the presence of increasing concentrations of EPO (1, 5, 
and 10 IU/ml, replenished to the culture every other day). and proliferation was detected by MTT assay. (C) Cell lines were cultured in the presence 
of PBS or EPO (1 IU/ml) for 16 hours and EdU for 1 hour. They were then analyzed for EdU incorporation by flow cytometry. (D) Indicated cell lines 
were treated with vehicle, etoposide (50 μM), or etoposide (50 μM) and EPO (10 IU/ml) for 24 hours. Whole cell extracts were western blotted with 
the indicated antibodies. (E) Indicated cell lines were treated with DMSO, etoposide (50 μM), or etoposide (50 μM) and EPO (10 IU/ml) for 24 hours. 
Percentage of apoptotic cells was then determined by flow analysis using Alexa Fluor 488 annexin V/PI Cell Apoptosis Kit (Invitrogen). ***P ≤ 0.001.
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Thus, orthotopic implantation of C3-Tag or MMTV-Neu cells and 
metastatic C3-Tag models recapitulate the in vivo EPO responsive-
ness of autochthonous GEMM tumors.
EPO increases mammosphere formation and promotes self-renewal. We 
hypothesized that EPO’s tumor promoting effects are seen in vivo 
but not with in vitro assays because it affects a limited fraction of 
cells, such as breast TICs. Thus, its effects might only be seen with 
a longer period of EPO administration, such as those achieved in 
vivo. We hypothesized that if we enriched for the EPO-responsive 
fraction of cells, we might be able to see its protumorigenic effects 
more rapidly. Therefore, we compared the impact of exogenous 
EPO on the ability of FACS-sorted (Supplemental Figure 6) sub-
populations of SUM149 cells: (a) CD44+CD24–EpCAM+ [TICs], (b) 
CD44+CD24–EpCAM– (non-TICs), and (c) CD44+CD24+EpCAM+)
non-TICs) to form mammospheres in vitro (Figure 4, A and B, and 
ref. 35). EPO significantly increased the number of spheres in the 
TIC fraction (Figure 4, A and B), but not in unsorted SUM149 cells 
or SUM149 cells from non-TIC fractions.
Furthermore, to determine the effects of EPO on breast TIC self 
renewal, PBS- and EPO-treated spheres were dissociated and pas-
saged for several generations. EPO-treated spheres had a higher 
sphere-forming efficiency and maintained a steady level of sphere-
forming activity over serial passage (Figure 4C). In contrast, PBS-
treated spheres had a progressive decrease in the capacity to form 
daughter spheres, with a significantly lower sphere-forming effi-
ciency by passage 4. Thus, stringent isolation of breast cancer cell 
populations revealed that the effects of EPO are remarkably specif-
ic in breast cancer in vitro, promoting the self renewal of a highly 
tumorigenic TIC fraction.
EPO promotes expansion of breast TICs in MMTV-Wnt1 breast tumors. 
Previous studies have defined TICs from the autochthonous breast 
tumors of MMTV-Wnt1 mice (36). In keeping with the results in 
SUM149 cells, in vitro exposure to exogenous EPO appeared to 
increase sphere formation by MMTV-Wnt1 TICs (Lin-Thy1+CD24+) 
(Figure 4, D and E). We next wanted to see whether EPO can pro-
mote the expansion of breast TICs in vivo as well. To this end, we 
randomized female FVB/N mice with orthotopically implanted 
MMTV-Wnt1 tumors to PBS or EPO treatment (Figure 4F). After 
4 weeks, the percentages of MMTV-Wnt1 TICs quantified by flow 
cytometry (Supplemental Figure 7A) were significantly higher in 
the tumors of mice that received EPO (Figure 4G and Supplemen-
tal Figure 7B). Moreover, cells from EPO-treated tumors showed 
Figure 3
EPO promotes progression of orthotopic C3-Tag and MMTV-Neu tumors. (A) 1 × 105 luciferase-expressing C3-Tag cells were implanted into the mam-
mary fat pads of FVB/N mice. The mice were randomized to receive PBS or EPO (500 IU/kg BIW). Representative Xenogen images of mice on day 1 
and day 21 after injection. (B) Living Image software (Caliper Life Sciences) was used to quantify luciferase activity of orthotopic C3-Tag tumors. Mean 
photons/s/cm2 is graphed with error bars representing SEM. *P ≤ 0.05 on day 21. (C) Tumor volume of orthotopically implanted NT2 cells as measured 
by calipers. ***P ≤ 0.001. (D and E) Kaplan-Meier curves of percentage of C3-Tag tail vein–injected mice alive in the indicated treatment groups.
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increased tumor- initiating capacity by in vivo limiting dilution 
assays (Table 1) (tumor initiating frequency: PBS, 1 in 2,166 [95% 
CI of 1,205–3,896]; EPO, 1 in 673 [95% CI of 435–1,041]). These 
results in aggregate demonstrate that exogenous EPO promotes 
the expansion and self-renewal of breast TICs in vitro and in vivo.
EPO stimulates JAK/STAT signaling in breast TICs. EPO activates the 
JAK/STAT pathway in hematopoietic erythroid precursors, and 
recent work has shown that CD44+CD24– stem cell–like breast 
cancer cells require JAK2/STAT3 signaling for growth (37). We 
therefore asked whether exogenous EPO activates JAK/STAT sig-
naling in breast TICs. We noted that SUM149 TICs had higher 
levels of EPO-R (Supplemental Figure 8) and higher basal levels 
of JAK/STAT activation, as evidenced by increased pSTAT3 in 
PBS-treated TICs relative to PBS-treated non-TICs (Figure 5A). In 
addition, EPO-treated TICs had induction of pJAK2 and pSTAT3, 
while EPO-treated non-TICs did not (Figure 5A).
Additionally, JAK/STAT activation in breast TICs resulted in 
changes in STAT-responsive genes, as microarrays performed 
on SUM149 TICs cultured overnight in the presence of EPO 
showed an enrichment of JAK/STAT gene signatures as well as 
gene signatures that characterize cancer stem cells or promote 
stem cell self renewal, such as the notch and hedgehog pathways 
(Figure 5B). Therefore, treatment of breast TICs with exogenous 
EPO not only upregulates JAK/STAT signaling but also induces 
functional gene expression changes indicative of STAT, hedge-
hog, and notch transcriptional activation.
Figure 4
EPO promotes mammosphere formation, TIC self renewal, and expansion of TICs in vivo. (A) Mammosphere formation of FACS-sorted SUM149 
cells. 20,000 cells from each subpopulation were plated in triplicate in 6-well plates. PBS or EPO (1 IU/ml) were added every other day, and colo-
nies (≥ 50 μm) were counted on day 5. (B) Representative photos of mammospheres from PBS- or EPO-treated SUM149 cells. Scale bars: 200 μm. 
(C) Primary mammospheres from SUM149 TICs (CD44+CD24–EpCAM+) were dissociated and serial passaged by replating 20,000 cells for 
each passage. TICs cultured in PBS showed a significant exhaustion of self-renewal capacity after passage 3. (D) Mammosphere formation of 
Lin–Thy1+CD24+ MMTV-Wnt1 cells cultured with PBS or EPO under 21% O2. Non-Lin–Thy+CD24+ cells did not grow spheres. (E) Representative 
photos of spheres from Lin-Thy1+CD24+ MMTV-Wnt1 cells treated with PBS or EPO. Original magnification, ×1. (F) Schematic of orthotopically 
implanted MMTV-Wnt1 tumors treated with PBS or EPO (500 IU/kg i.p. twice a week) for 4 weeks then assessed for TIC frequency by flow cytom-
etry and LDA. (G) MMTV-Wnt1 orthotopic tumors were harvested and stained with antibodies specific to Thy1, CD24, a lineage cocktail, and 
DAPI. There were a significantly higher percentage of Lin–Thy+CD24+ cells in tumors of mice treated with EPO. **P ≤ 0.01; ***P ≤ 0.001.
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Neutralizing antibodies to EPO or EPO-R abrogate hypoxia-induced 
mammosphere formation. Hypoxia is known to increase TIC self-
renewal, and EPO is a well-established hypoxia-inducible gene 
(38). To determine the contribution of endogenous EPO to hypox-
ia-induced mammosphere formation, we assessed sphere forma-
tion of SUM149 TICs in the presence of increasing concentrations 
of neutralizing antibodies to EPO, 2 independent EPO-R antibod-
ies, or control antibody (anti-HA) (Figure 5, C and D). Both EPO 
and EPO-R neutralizing antibodies decreased EPO-induced ERK 
activation (Supplemental Figure 9) as well as hypoxia-induced 
mammosphere formation (Figure 5, C and D), suggesting that 
endogenous EPO and EPO-R signaling are necessary for the 
hypoxia-induced clonogenicity of breast TICs.
JAK2 inhibition abrogates EPO-induced mammosphere formation and 
is synergistic with chemotherapy in vivo. Exogenous EPO treatment of 
breast TICs promotes mammosphere formation (Figure 4, A–E) 
and JAK/STAT activation (Figure 5, A and B). We asked whether 
pharmacologic JAK2 inhibition using the orally available JAK2 
kinase inhibitor TG101348 (TargeGen) (39) inhibits sphere for-
mation. In keeping with the notion that JAK2 signaling is critical 
for mammosphere formation by breast TICs, we saw a dose-depen-
dent reduction in sphere formation by TG101348 (Figure 5E).
While JAK2 inhibition may be effective at limiting breast TIC 
self-renewal (Figure 5E), the lack of JAK2 activation in the non-
TICs suggested that it may not be effective on this population 
of cells. We therefore hypothesized that combining JAK2 inhibi-
tion with chemotherapy might be necessary to target TICs and 
non-TICs, respectively. In keeping with this notion, orthotopic 
Wnt1 tumors treated with the combination of carboplatin and 
TG101348 had a statistically significant decrease in tumor volume 
relative to vehicle treatment, treatment with single-agent carbopla-
tin, or treatment with single-agent TG101348 (Figure 5F). More-
over, the addition of TG101348 to carboplatin did not appear to 
induce significantly more anemia (the primary dose-limiting toxic-
ity of JAK2 inhibition) (Figure 5G). Therefore, the combination of 
chemotherapy with JAK2 inhibition appears to have potential for 
the treatment of breast cancer.
Endogenous EPO correlates negatively with relapse-free survival and is 
expressed by breast cancer cells and tumor-associated endothelial cells. We 
hypothesized that endogenous EPO exists in the tumor microen-
vironment and that EPO levels might therefore correlate with the 
clinical outcome of women with breast cancer. We interrogated 
2 independent microarray data sets of early stage breast cancers 
(GEO GSE18229 and GSE26338) (40, 41) and found that high 
EPO expression was significantly associated with a decreased 
probability of relapse (Figure 6A) as well as enrichment in STAT 
gene signatures (Supplemental Figure 10). Thus, endogenous 
EPO expression in primary tumors correlates 
with clinical outcome.
While EPO is primarily produced in the 
kidney, a number of other tissues, a broad 
spectrum of cancer cell lines, and primary 
tumors have also been shown to produce 
EPO (6, 7, 42–44). We found that endog-
enous EPO was hypoxia inducible in breast 
cancer cell lines (Figure 6, B and C), but not 
human mammary epithelial cells (HMECs). 
Additionally, we examined several of the cel-
lular compartments within breast tumors 
for their ability to produce endogenous 
EPO and found that RNA from laser-captured, tumor-associ-
ated endothelial cells had higher levels of EPO than endothelial 
cells from adjacent normal tissue (Figure 6D and ref. 45). How-
ever, primary cultures of cancer associated fibroblasts (CAF) 
from human breast tumors of luminal (CAF9) and basal-like 
(CAF7J) breast cancers did not have appreciable hypoxia-induc-
ible EPO mRNA or protein when cultured under hypoxia (Sup-
plemental Figure 11, A and B), nor did HUVECs (Figure 6E). 
In aggregate, these data enforce the notion of the biologic com-
plexity of tumors and suggest that both breast cancer cells and 
tumor-associated endothelial cells may produce EPO and that 
increased EPO expression correlates with shortened relapse-free 
survival in breast cancer.
Discussion
rHuEPO was developed with the best of intentions. While it 
decreases the transfusion requirements and improves the quality 
of life of cancer patients, randomized trials have demonstrated 
that rHuEPO administration is associated with shorter progres-
sion-free and overall survival (11–17). A more definitive under-
standing of how EPO is protumorigenic is important. First, it 
would allow the design of novel ESAs that promote erythropoi-
esis but not tumorigenicity. Second, it might define whether all 
patients or only specific subgroups should be excluded from ESA 
use. Finally, it may give us insight into the role that endogenous 
EPO plays in tumor progression. Efforts to assess the protumori-
genic effects of EPO have been particularly hampered by the lack 
of in vivo models to test hypotheses. Our experiments identify 
relevant GEMMs of breast cancer in which autochthonous breast 
tumors are sensitive to the growth-promoting effects of EPO and 
are sensitive to JAK/STAT inhibition.
Recent data from a loss-of-function screen identified the JAK2/
STAT3 pathway as being necessary for the growth of basal-like, 
stem-like breast cancer cells and suggested that IL-6 was the pri-
mary mediator of normoxic JAK/STAT signaling (37). Notably 
however, breast TICs were never enriched for in this study, and 
therefore their data were derived primarily from comparisons of 
basal-like with luminal breast cancer cell lines. Our experiments 
therefore refine and extended these observations via a functional 
analysis of the effects of JAK/STAT signaling in a highly enriched 
population of TICs (the CD44+CD24–EpCAM+ fraction) (35) and 
identify EPO as a hypoxia-induced activator of JAK/STAT signal-
ing and cancer cell stemness. Along these lines, a previous report 
also demonstrated that EPO increased the numbers and self 
renewal of breast cancer–initiating cells (CICs), yet in contrast to 
our studies, identified notch, rather than the JAK/STAT pathway, 
as a key regulator of self renewal (46).
Table 1
EPO promotes expansion of tumor-initiating capacity of breast TICs from  
MMTV-Wnt1 tumors
Cells injected 2,000 1000 500 250 100 TIC capacity
PBS treated 5/6 3/10 2/12 1/13 0/6 1 in 2,166 (1,205–3,896A)
EPO treated 6/6 8/10 6/12 3/13 1/6 1 in 673 (435–1,041A)
A95% CI. Cells dissociated from PBS- or EPO-treated MMTV-Wnt1 orthotopic tumors were 
injected into the mammary fat pads of female FVB mice at the indicated cell numbers. Tumor-
initiating capacity and CIs (95%) were calculated using L-Calc limiting dilution software 7 weeks 
after inoculation.
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Figure 5
EPO activates JAK/STAT signaling in breast TICs, and JAK inhibition is a potential therapeutic target in breast cancer. (A) SUM149 cells were 
FACS sorted into TIC (CD44+CD24–EpCAM+) and non-TIC (not CD44+CD24–EpCAM+) populations, treated with PBS or EPO (1 IU/ml) for 10 
minutes, and immunoblotted with the indicated antibodies. (B) Gene-expression profiles were generated from total RNA of sorted SUM149 TICs 
(CD44+CD24–EpCAM+), treated with PBS or EPO (1IU/ml) for 16 hours,and subjected to ssGSEA for the indicated JAK/STAT and cancer stem 
cell gene signatures. (C) Mammosphere formation of CD44+CD24–EpCAM+ SUM149 cells cultured at hypoxia (2% O2) in the presence of control 
antibody (anti-HA) or anti-EPO antibody at the indicated dilutions. (D) Mammosphere formation of CD44+CD24–EpCAM+ SUM149 cells cultured 
at hypoxia (2% O2) in the presence of control antibody (anti-HA) or 2 indicated anti-EPOR antibodies (1:200). (E) 20,000 (CD44+CD24–EpCAM+) 
SUM149 cells were plated in duplicate in the presence of EPO (10 IU/ml) and vehicle or EPO and the JAK inhibitor TG101348 at the indicated 
concentrations. Spheres were counted on day 5. (F) Orthotopic MMTV-Wnt1 tumors were grown to 5 mm in length and width (average tumor vol-
ume of all groups = 60 mm3) and treated with vehicle (NT), carboplatin (Carbo), TG101348 (TG), or the combination of carboplatin and TG101348. 
Caliper measurements were taken weekly. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001. (G) Hematocrit (HCT) measurements were done at baseline and 
at end point in the indicated treatment groups.
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A recent report suggests that EPO antagonizes treatment with 
the anti-HER2 antibody trastuzumab by activating EPO-R/JAK2 
downstream effectors, effectively bypassing HER2 signaling (47). 
While mechanistically satisfying, this result only explains the ther-
apeutic antagonism between EPO and trastuzumab in women with 
HER2+ breast cancer, which represents approximately 15%–20% of 
patients. Moreover, it should result in therapeutic antagonism 
only in women being actively treated with anti-HER2 agents. The 
fact that EPO’s negative effects have been seen in a wide variety of 
tumor types and in anemic cancer patients not undergoing treat-
ment argue strongly that there are other, non-HER2–related ways 
in which EPO promotes tumor progression (17, 48). These clinical 
studies along with our data in both the C3-Tag and MMTV-Neu 
GEMMs are strong evidence that the negative effects of EPO are 
not merely a result of therapeutic antagonism to trastuzumab.
Finally, our studies support a role for endogenous EPO in 
breast tumorigenesis. Our studies suggest that both breast can-
cer cells and cancer-associated endothelial cells are potential 
sources of intratumoral EPO (Figure 7). While we did not see 
appreciable hypoxia-inducible EPO expression from CAFs, others 
have reported that tumor-associated stromal cells are a source of 
PDGF-dependent EPO production (49). Nonetheless, hypoxia-
dependent breast TIC self renewal is dependent upon EPO and 
is correlated with relapse-free survival in breast cancer patients. 
Moreover, we identify the therapeutic potential of combining the 
JAK2 inhibitor TG101348 with carboplatin chemotherapy in vivo 
and postulate that this synergistic effect was seen because of the 
ability of TG101348 and carboplatin to target the TIC and bulk 
populations of breast cancer cells, respectively. This is particularly 
interesting in light of the fact that the JAK2 inhibitor ruxolitinib 
(Jakafi), is now FDA approved for the treatment of patients with 
JAK2 mutant myelofibrosis, and clinical trials using ruxolitinib are 
ongoing in women with breast cancer.
In summary, we have identified tractable GEMMs of breast cancer 
in which autochthonous tumors are sensitive to the protumorigenic 
effects of EPO. EPO promotes self-renewal and enhances TIC expan-
sion of breast TICs in vitro and in vivo. Finally, our studies define an 
active role for endogenous EPO produced within tumors and show 
that JAK2 inhibition in combination with chemotherapy is a prom-
ising therapeutic strategy in the treatment of breast cancer.
Methods
Cell culture. MDA-MB231, SKBR3, and MCF7 cell lines were obtained from 
ATCC and cultured according to their recommendations. SUM149 cells 
(Asterand) were maintained in HuMEC basal medium and supplements 
(Gibco; Life Technologies) and 5% FBS and 100 U/ml penicillin/streptomy-
cin. HMEC cells (50) were cultured in HuMEC ready medium (Gibco; Life 
Technologies). The C3-Tag cell line was established by dissociation of C3-Tag 
mammary tumors with 0.25% Trypsin, followed by differential trypsiniza-
tion to remove fibroblasts. C3-Tag-luc cells were generated by stably trans-
Figure 6
Endogenous EPO expression correlates negatively with relapse-free survival and is produced by breast cancer cell lines and tumor endothelial 
cells. (A) Breast tumors (337 patients [GSE18229] and 855 patients [GSE26338] were rank ordered based on their EPO expression and divided 
into those with high and low EPO expression (high: top 2 tertiles, low: bottom tertile). P = 0.0088 for UNC337, P = 0.0012 for GSE26338, log rank 
test. (B) EPO mRNA levels from HMECs and the indicated breast cancer cell lines cultured in 21% and 1% O2 using TaqMan quantitative RT-PCR. 
(C) EPO protein as measured by ELISA on conditioned medium from the indicated cell lines after culture under 21% O2 or 1% O2 for 16 hours. (D) 
Microarray gene expression for EPO was abstracted from a publically available data set (GSE7413) in which breast cancer–associated endothelial 
cells or endothelial cells from adjacent normal were laser capture microdissected. Relative gene expression Cy5 (tumor)/Cy3(reference) is shown. 
(E) EPO mRNA levels from HUVECs cultured in 21% and 1% O2 were measured by TaqMan quantitative PCR. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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protein assay, and 20 μg of whole-cell lysates was used for SDS-PAGE. 
Membranes were blocked with 5% milk or BSA diluted in 1× TBST for 
1 hour and incubated at 4°C overnight with one of the following primary 
antibodies: phospho-Jak2 (Tyr1007/1008) (cat. #3771:1:1000; Cell Signal-
ing Technology), Jak2 (D2E12) (cat. #3230, 1:1000; Cell Signaling Tech-
nology), phospho-Stat3 (Tyr705) (cat. #9145, 1:1000; Cell Signaling Tech-
nology), cleaved caspase 3 (cat. #9662, 1:1000; Cell Signaling Technology), 
and Stat3 (cat. #8768; Cell Signaling Technology). Immunoblots against 
actin (sc-1615, 1:5000; Santa Cruz Biotechnology Inc.) were used as load-
ing controls. The membranes were then probed with secondary antibodies 
(HRP-conjugated goat anti-rabbit and goat anti-mouse, cat. #31462 and 
#31432, respectively, 1:5000; Thermo Scientific), and immunoreactions 
were detected with Amersham Biosciences ECL (GE Healthcare).
EPO ELISA. Five million cells were plated in 10 cm dishes in 6 ml of 
serum-free medium and cultured under either normoxia (21% O2) or 
hypoxia (1% O2) for 16 hours. Media were then collected and concentrated 
to 200 μl using Ultra-15 centrifugal filter units (cut-off 10 kDa; Millipore). 
EPO levels were assayed in duplicate using a human ELISA kit (Stem Cell 
Technologies) following the manufacturer’s instructions.
Total RNA Isolation and real-time quantitative PCR. Total RNA was iso-
lated using the RNAeasy Mini Kit (QIAGEN Sciences) following the 
manufacturer’s instructions. One microgram of purified total RNA was 
used for reverse transcription with ImProm-11 Reverse Transcription 
System (Promega) according to the manufacturer’s instructions. Expres-
sion of all transcripts was determined by using commercially available 
assays from Applied Biosystems. Transcript expression levels of human 
EPO (HS01071097), 18S ribosomal RNA (Hs03003631) and GAPDH 
ducing C3-Tag cells with retrovirus expressing pMMP-Luc-Neo construct. 
C3-Tag cells were maintained in DMEM (Cellgro) with 10% FBS and 1% peni-
cillin/streptomycin. All cell lines were grown at 37°C and 5% CO2. The NT2 
cell line was provided by Jonathan Serody (University of North Carolina– 
Chapel Hill [UNC-CH]) and Elizabeth Jaffee (Johns Hopkins University).
Cell staining and flow cytometry. Quantification of apoptosis of the cell 
lines was performed by staining for annexin V and propidium iodide (PI). 
Cells were treated with vehicle, etoposide (50, 100 μM), or etoposide in 
combination with EPO (10 IU/ml) for 12 hours in serum-free medium. 
Percentage of apoptotic cells was determined by flow analysis using the 
Alexa Fluor 488/annexin V/PI Cell Apoptosis Kit (Invitrogen) according 
to the manufacturer’s instructions. Cell-cycle analysis of vehicle-treated or 
EPO-treated (10 IU/ml) cells was performed by EdU incorporation using 
Click-iT EdU Alexa Fluor 647 Flow Assay Kit (Invitrogen) according to the 
manufacturer’s instructions.
Flow cytometry to enrich for breast TICs was performed as previously 
described (35, 36). Briefly, cells were stained at a concentration of 1 × 106 
cells per 100 μl of HBSS with 2% FBS. Fluorescent-conjugated antibodies 
(Supplemental Table 1) at appropriate dilutions were added. Cells were 
stained for 30 minutes on ice, washed with staining medium, and resus-
pended in staining medium containing DAPI (final concentration, 1 μg/ml). 
Multi-color flow cytometry was performed on a CyAnTM ADP flow cytom-
eter (Dako), and data analysis was performed using FlowJo software (Tree 
Star Inc.). A portion of double-sorted cells was reanalyzed to ensure purity. 
Final cell purity was greater than 95%.
Western blot analysis. Cells were washed twice with PBS and harvested in 
RIPA lysis buffer. Protein concentration was determined with Bio-Rad 
Figure 7
Sources of EPO and proposed 
mechanism of EPO-promoting 
breast TIC self renewal. Intratumoral 
EPO may be derived from several 
intratumoral cells including stromal 
cells, cancer-associated endothelial 
cells, and breast cancer cells as 
well as exogenous administration. 
Intratumoral EPO activates EPO-R 
present on breast TICs that subse-
quently activates JAK/STAT signal-
ing promoting TIC self renewal and 
stemness. Potential effects of EPO 
on the non-TIC fraction will need to 
be investigated. The JAK inhibitor 
TG101348 inhibits JAK/STAT signal-
ing and EPO-dependent breast TIC 
self renewal.
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mg/kg/d, crow), or a combination of carboplatin and TG101348 (37.5 mg/
kg/d and 240 mg/kg/d i.p. respectively).
LDA assay. MMTV-Wnt1 orthotopic tumors were dissociated and the 
indicated number of DAPI–Lin– tumor cells were then implanted into the 
mammary fat pads of FVB mice. Mice were observed weekly for 2 months 
for tumor formation. Tumorigenic cell frequencies were calculated using 
L-Calc (StemCell Technologies).
Complete blood counts. Hematocrit measurements were run on a Hemavet 
950 hematology system (Drew Scientific).
Microarray and GSEA. TICs (CD44+CD24–EpCAM+) from SUM149 cells 
were sorted as described above. After sorting, 10,000 cells were resuspended 
in MammoCult Basal Medium and starved for 2 hours, then treated with 
either PBS or EPO (1 IU/ml) for 16 hours. Total RNA was extracted from 
2 independent sortings. All samples were profiled as described previously 
using oligo microarrays (Agilent Technologies) and uploaded to NCBI 
Gene Expression Omnibus (GSE51433) (53). All microarray and patient 
clinical data are available in the UNC-CH Microarray Database (https://
genome.unc.edu/pubsup/breastGEO/clinicalData.shtml). single-sample 
gene set enrichment analysis (ssGSEA) (Broad Institute) was performed 
on log-transformed median centered data. All gene sets are part of the 
Molecular Signature Database v3.1 curated gene sets (http://www.broad.
mit.edu/gsea/msigdb/).
For additional information, see Supplemental Methods.
Statistics. Mouse Kaplan-Meier tumor-free or overall survival was ana-
lyzed using GraphPad Prism 4.0 software (GraphPad Software Inc.), and 
comparisons were made using the log-rank test. Tumor sizes were com-
pared using an unpaired, 2-tailed t test. Human Kaplan-Meier relapse-free 
survival was analyzed in R (http://www.r-project.org/) using the library 
survival in the R project. All data are graphed as mean ± SEM, unless oth-
erwise noted. All box and whisker plots represent 25th to 75th percentiles, 
with whiskers representing the range and the line denoting the median 
value. P < 0.05 was considered significant.
Study approval. All studies involving mice were performed with approval 
from the IACUCs at UNC-CH.
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(Hs0392909), and relative gene expression were calculated according to 
the 2–ΔΔCt method, as previously described (51).
Mammosphere assay. Mammosphere assays were performed according to 
the protocol from StemCell Technologies. Briefly, 20,000 sorted or unsort-
ed SUM149 cells per well were grown in 6-well Ultra Low Attachment 
Plates (Corning) in 2 ml of Complete MammoCult Medium (MammoCult 
Basal Medium supplied with 10% Mammocult proliferation supplement, 
4 μg/ml heparin, and 0.48 μg/ml hydrocortisone; all purchased from Stem-
Cell Technologies). EPO was added (10 IU/ml) every other day, and spheres 
(size ≥ 50 μm) were counted on day 5.
EPO neutralization experiments were performed using anti-EPO anti-
body (H-162: sc-7956; Santa Cruz Biotechnology Inc.). EPO-R neutraliza-
tion was performed using anti-EPOR antibodies (C-20 and M-20; Santa 
Cruz Biotechnology Inc.). TG101348 was synthesized by the UNC-CH 
Center for Integrative Chemical Biology and Drug Discovery based on its 
publically available structure.
Serial sphere assay. Mammospheres were passaged using 0.05% trypsin/0.53 
mmol/l EDTA-4Na and filtered through a 40-μM cell strainer. 20,000 dis-
sociated cells per well were replated in 2 ml mammosphere medium as 
above. Sphere-forming efficiency was calculated by dividing the number of 
mammospheres formed by the original number of single cells seeded and 
is expressed as a percentage. Each experiment was performed in triplicate.
MMTV-Wnt1 sphere assays. Mouse MMTV-Wnt1 tumors were minced with 
a razor blade and suspended in 10 ml of L-15 Leibovitz medium (Thermo 
Scientific) supplemented with 500 μl of collagenase/hyaluronidase (cat. 
#07912; Stem Cell Technologies). Tumors were digested for 2 hours at 
37°C with pipetting every 30 minutes. Then, HBSS with 2% HICS was 
added to inactivate the collagenases. After pelleting, cells were treated 
serially with trypsin, dispase, DNase, and ACK lysis buffer. Cells were 
then stained with lineage cocktail (antibodies against CD31, CD45, and 
CD140a) and antibodies against CD49f and CD24 in HBSS with 2% HICS. 
Viable, Lin–CD24hiCD49fhi cells were sorted and cultured in Matrigel with 
vehicle or EPO (1 IU/ml) in DMEM/F12 medium with 2% B27, 20 ng/ml 
murine EGR, 20 ng/ml recombinant basic FGF, and 1% penicillin/strepto-
mycin. After 10–14 days, colonies were counted using Clono-Counter (52).
Mouse colony and orthotopic injections. FVB/NJ, C3-Tag, and MMTV-Neu 
mice were purchased from the Jackson Laboratory.
For the GEMMs of breast cancer studies, 6-week-old virgin C3-Tag mice 
were treated with i.p. injections of either saline (PBS) or Procrit (EPO; 
Amgen). MMTV-Neu mice began EPO treatment 4 weeks after parturition; 
mice were dosed i.p. 500 IU/kg biweekly (BIW). Mice were sacrificed when 
maximum tumor size (1.3 cm) was reached.
For orthotopic injection of C3-Tag-luc cells, cells were trypsinized and 
resuspended in HBSS with 2% FBS. 1 × 105 cells were resuspended in 100 μl 
of HBSS/Matrigel (354234; BD Biosciences), mixed (1:1 volume), and 
injected into the lower right mammary fat pad of FVB/NJ female mice 
(6–8 weeks of age). Administration of saline or EPO (500 IU/kg, BIW) was 
started 1 week after the injection. Bioluminescence imaging was done 
using IVIS Kinetic Optical System.
MMTV-Wnt-1 tumor cells were dissociated with gentleMACS dis-
sociator (Miltenyi Biotec Inc.) following the manufacturer’s instruc-
tions for making single-cell suspensions from implanted mouse tumors. 
2 × 105 cells were injected into the lower right mammary fat pads of FVB/
NJ female mice as described for the C3-Tag-luc cells (n = 40). When ortho-
topic tumors reached 5 mm in length and width, mice were randomized to 
treatment with vehicle, carboplatin (37.5 mg/kg/d, i.p.), TG101348 (240 
 1. Kaelin WG, Ratcliffe PJ. Oxygen sensing by meta-
zoans: the central role of the HIF hydroxylase path-
way. Mol Cell. 2008;30(4):393–402.
 2. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. 
The erythropoietin receptor in normal and cancer 
tissues. Crit Rev Oncol Hematol. 2008;67(1):39–61.
 3. Kim WY, et al. Failure to prolyl hydroxylate hypoxia- 
inducible factor alpha phenocopies VHL inactiva-
tion in vivo. EMBO J. 2006;25(19):4650–4662.
 4. Gruber M, et al. Acute postnatal ablation of Hif-
2α results in anemia. Proc Natl Acad Sci U S A. 2007; 
104(7):2301–2306.
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 2   February 2014 563
 5. Scortegagna M, et al. HIF-2α regulates murine 
hematopoietic development in an erythropoietin-
dependent manner. Blood. 2005;105(8):3133–3140.
 6. Jelkmann W. Developments in the therapeutic use 
of erythropoiesis stimulating agents. Br J Haematol. 
2008;141(3):287–297.
 7. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpat-
rick JP, Dewhirst MW. Erythropoietin biology in 
cancer. Clin Cancer Res. 2006;12(2):332–339.
 8. Farrell F. The Erythropoietin Receptor and its 
expression in tumor cells and other tissues. Oncolo-
gist. 2004;9(suppl 5):18–30.
 9. Parganas E, et al. Jak2 is essential for signaling 
through a variety of cytokine receptors. Cell. 1998; 
93(3):385–395.
 10. Spivak JL. The anaemia of cancer: death by a thou-
sand cuts. Nat Rev Cancer. 2005;5(7):543–555.
 11. Glaspy J, et al. Impact of therapy with epoetin alfa 
on clinical outcomes in patients with nonmyeloid 
malignancies during cancer chemotherapy in com-
munity oncology practice. Procrit Study Group. 
J Clin Oncol. 1997;15(3):1218–1234.
 12. Henke M, et al. Erythropoietin to treat head and 
neck cancer patients with anaemia undergoing 
radiotherapy: randomised, double-blind, placebo-
controlled trial. Lancet. 2003;362(9392):1255–1260.
 13. Demetri GD, Kris M, Wade J, Degos L, Cella D. 
Quality-of-life benefit in chemotherapy patients 
treated with epoetin alfa is independent of disease 
response or tumor type: results from a prospective 
community oncology study. Procrit Study Group. 
J Clin Oncol. 1998;16(10):3412–3425.
 14. Leyland-Jones B, et al. Maintaining normal hemo-
globin levels with epoetin α in mainly nonanemic 
patients with metastatic breast cancer receiving 
first-line chemotherapy: a survival study. J Clin 
Oncol. 2005;23(25):5960–5972.
 15. Gabrilove JL, et al. Clinical evaluation of once-
weekly dosing of epoetin alfa in chemotherapy 
patients: improvements in hemoglobin and qual-
ity of life are similar to three-times-weekly dosing. 
J Clin Oncol. 2001;19(11):2875–2882.
 16. Wright JR, et al. Randomized, double-blind, placebo- 
controlled trial of erythropoietin in non-small-
cell lung cancer with disease-related anemia. J Clin 
Oncol. 2007;25(9):1027–1032.
 17. Smith RE, et al. Darbepoetin α for the treatment of 
anemia in patients with active cancer not receiving 
chemotherapy or radiotherapy: results of a phase 
III, multicenter, randomized, double-blind, placebo-
controlled study. J Clin Oncol. 2008;26(7):1040–1050.
 18. Littlewood TJ, et al. Effects of epoetin α on hema-
tologic parameters and quality of life in cancer 
patients receiving nonplatinum chemotherapy: 
results of a randomized, double-blind, placebo-con-
trolled trial. J Clin Oncol. 2001;19(11):2865–2874.
 19. Savonije JH, et al. Effects of early intervention with 
epoetin α on transfusion requirement, hemoglobin 
level and survival during platinum-based chemo-
therapy: Results of a multicenter randomised con-
trolled trial. Eur J Cancer. 2005;41(11):1560–1569.
 20. Chang J, Couture F, Young S, McWatters K-L, 
Lau CY. Weekly epoetin α maintains hemoglobin, 
improves quality of life, and reduces transfusion 
in breast cancer patients receiving chemotherapy. 
J Clin Oncol. 2005;23(12):2597–2605.
 21. Vansteenkiste J, et al. Double-blind, placebo-con-
trolled, randomized phase III trial of darbepoetin 
α in lung cancer patients receiving chemotherapy. 
J Natl Cancer Inst. 2002;94(16):1211–1220.
 22. Hardee ME, et al. Erythropoietin inhibits apoptosis 
in breast cancer cells via an Akt-dependent pathway 
without modulating in vivo chemosensitivity. Mol 
Cancer Ther. 2006;5(2):356–361.
 23. Arcasoy MO. Erythropoiesis-stimulating agent use 
in cancer: preclinical and clinical perspectives. Clin 
Cancer Res. 2008;14(15):4685–4690.
 24. Hedley BD, et al. Recombinant human erythropoi-
etin in combination with chemotherapy increases 
breast cancer metastasis in preclinical mouse mod-
els. Clin Cancer Res. 2011;17(19):6151–6162.
 25. Lee AS, et al. Erythropoietin induces lymph node 
lymphangiogenesis and lymph node tumor metas-
tasis. Cancer Res. 2011;71(13):4506–4517.
 26. Lai SY, et al. Erythropoietin-mediated activation 
of JAK-STAT signaling contributes to cellular inva-
sion in head and neck squamous cell carcinoma. 
Oncogene. 2005;24(27):4442–4449.
 27. Lopez TV, et al. Autocrine/paracrine erythropoietin 
signalling promotes JAK/STAT-dependent prolif-
eration of human cervical cancer cells. Int J Cancer. 
2011;129(11):2566–2576.
 28. Okazaki T, et al. Erythropoietin promotes the 
growth of tumors lacking its receptor and decreas-
es survival of tumor-bearing mice by enhancing 
angiogenesis. Neoplasia. 2008;10(9):932–939.
 29. LaMontagne KR, et al. Recombinant epoetins do not 
stimulate tumor growth in erythropoietin receptor-
positive breast carcinoma models. Mol Cancer Ther. 
2006;5(2):347–355.
 30. Sinclair AM, et al. Expression and function of 
erythropoietin receptors in tumors. Cancer. 2007; 
110(3):477–488.
 31. Hardee ME, et al. Human recombinant erythro-
poietin (rEpo) has no effect on tumour growth or 
angiogenesis. Br J Cancer. 2005;93(12):1350–1355.
 32. Blackwell KL, et al. Human recombinant erythro-
poietin significantly improves tumor oxygenation 
independent of its effects on hemoglobin. Cancer 
Res. 2003;63(19):6162–6165.
 33. Maroulakou IG, Anver M, Garrett L, Green JE. Pros-
tate and mammary adenocarcinoma in transgenic 
mice carrying a rat C3(1) simian virus 40 large tumor 
antigen fusion gene. Proc Natl Acad Sci U S A. 1994; 
91(23):11236–11240.
 34. Guy CT, et al. Expression of the neu protooncogene 
in the mammary epithelium of transgenic mice 
induces metastatic disease. Proc Natl Acad Sci U S A. 
1992;89(22):10578–10582.
 35. Fillmore CM, Kuperwasser C. Human breast cancer 
cell lines contain stem-like cells that self-renew, give 
rise to phenotypically diverse progeny and survive 
chemotherapy. Breast Cancer Res. 2008;10(2):R25.
 36. Cho RW, et al. Isolation and molecular characteriza-
tion of cancer stem cells in MMTV-Wnt-1 murine 
breast tumors. Stem Cells. 2008;26(2):364–371.
 37. Marotta LLC, et al. The JAK2/STAT3 signaling 
pathway is required for growth of CD44+CD24– 
stem cell-like breast cancer cells in human tumors. 
J Clin Invest. 2011;121(7):2723–2735.
 38. Li Z, et al. Hypoxia-inducible factors regulate 
tumorigenic capacity of glioma stem cells. Cancer 
Cell. 2009;15(6):501–513.
 39. Wernig G, et al. Efficacy of TG101348, a selective 
JAK2 inhibitor, in treatment of a murine model of 
JAK2V617F-induced polycythemia vera. Cancer Cell. 
2008;13(4):311–320.
 40. Prat A, et al. Phenotypic and molecular charac-
terization of the claudin-low intrinsic subtype of 
breast cancer. Breast Cancer Res. 2010;12(5):R68.
 41. Harrell JC, et al. Genomic analysis identifies unique 
signatures predictive of brain, lung, and liver relapse. 
Breast Cancer Res Treat. 2012;132(2):523–535.
 42. Masuda S, et al. A novel site of erythropoietin produc-
tion. Oxygen-dependent production in cultured rat 
astrocytes. J Biol Chem. 1994;269(30):19488–19493.
 43. Yasuda Y, et al. Estrogen-dependent production of 
erythropoietin in uterus and its implication in uterine 
angiogenesis. J Biol Chem. 1998;273(39):25381–25387.
 44. Wang GL, Semenza GL. Characterization of 
hypoxia-inducible factor 1 and regulation of DNA 
binding activity by hypoxia. J Biol Chem. 1993; 
268(29):21513–21518.
 45. Bhati R, et al. Molecular characterization of human 
breast tumor vascular cells. Am J Pathol. 2008; 
172(5):1381–1390.
 46. Phillips TM, Kim K, Vlashi E, McBride WH, Pajonk F. 
Effects of recombinant erythropoietin on breast can-
cer-initiating cells. Neoplasia. 2007;9(12):1122–1129.
 47. Liang K, et al. Recombinant human erythropoietin 
antagonizes trastuzumab treatment of breast can-
cer cells via Jak2-mediated Src activation and PTEN 
inactivation. Cancer Cell. 2010;18(5):423–435.
 48. Gabrilove JL, Perez EA, Tomita DK, Rossi G, Clee-
land CS. Assessing symptom burden using the M. D. 
Anderson symptom inventory in patients with che-
motherapy-induced anemia: results of a multicenter, 
open-label study (SURPASS) of patients treated with 
darbepoetin-alpha at a dose of 200 microg every 2 
weeks. Cancer. 2007;110(7):1629–1640.
 49. Xue Y, et al. PDGF-BB modulates hematopoiesis and 
tumor angiogenesis by inducing erythropoietin pro-
duction in stromal cells. Nat Med. 2011;18(1):100–110.
 50. Troester MA, et al. Cell-type-specific responses to 
chemotherapeutics in breast cancer. Cancer Res. 
2004;64(12):4218–4226.
 51. Livak KJ, Schmittgen TD. Analysis of relative gene 
expression data using real-time quantitative PCR 
and the 2(-Delta Delta C(T)) Method. Methods. 
2001;25(4):402–408.
 52. Niyazi M, Niyazi I, Belka C. Counting colonies of 
clonogenic assays by using densitometric software. 
Radiat Oncol. 2007;2(1):4.
 53. Kim WY, et al. HIF2α cooperates with RAS to 
promote lung tumorigenesis in mice. J Clin Invest. 
2009;119(8):2160–2170.
